CHRS
Coherus BioSciences Inc
NASDAQ: CHRS · HEALTHCARE · BIOTECHNOLOGY
$1.74
-1.69% today
Updated 2026-04-29
Market cap
$262.31M
P/E ratio
—
P/S ratio
6.22x
EPS (TTM)
$-1.56
Dividend yield
—
52W range
$1 – $3
Volume
1.3M
Coherus BioSciences Inc (CHRS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
398.40%
Operating margin
-339.50%
ROE
33.10%
ROA
-31.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | $1.90M | $-33.02M | -1,737.07% | -2,028.33% | -1,738.70% |
| 2013 | $2.75M | $-53.63M | -1,037.00% | -1,308.36% | -1,949.65% |
| 2014 | $31.11M | $-87.13M | -151.48% | -207.94% | -280.12% |
| 2015 | $30.04M | $-223.26M | -607.97% | -729.23% | -743.18% |
| 2016 | $190.11M | $-127.34M | -33.84% | -60.98% | -66.98% |
| 2017 | $1.56M | $-238.17M | -10,216.90% | -14,918.77% | -15,306.56% |
| 2018 | $1.56M | $-209.34M | -107.90% | -13,137.28% | -13,453.66% |
| 2019 | $356.07M | $89.83M | 95.20% | 30.27% | 25.23% |
| 2020 | $475.82M | $132.24M | 92.08% | 32.85% | 27.79% |
| 2021 | $326.55M | $-287.10M | 82.36% | -80.80% | -87.92% |
| 2022 | $211.04M | $-291.75M | 66.79% | -121.72% | -138.24% |
| 2023 | $257.24M | $-237.89M | 38.19% | -78.99% | -92.48% |
| 2024 | $266.96M | $28.51M | 55.97% | -41.83% | 10.68% |
| 2025 | $42.17M | $-170.29M | 67.24% | -429.51% | -403.80% |